Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Clinical Trial
Official title:
A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma
This phase II trial study has a 6-patient feasibility portion studying the tolerability of chemotherapy with vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients with refractory or first recurrent extracranial Ewing's sarcoma. If the therapy is considered tolerable, this feasibility run-in will be followed by a randomized phase II portion studying giving vincristine sulfate together with topotecan hydrochloride, and cyclophosphamide to see how well it works compared with giving vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients with refractory or first recurrent extracranial Ewing's sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, topotecan hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop tumor growth by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.
PRIMARY OBJECTIVES:
I. To determine the feasibility of administering bevacizumab in combination with vincristine
(vincristine sulfate), topotecan hydrochloride, and cyclophosphamide (VTC) to younger
patients with refractory or first recurrent Ewing sarcoma.
II. To compare the progression-free survival of patients treated with VTC with bevacizumab
vs VTC without bevacizumab.
SECONDARY OBJECTIVES:
I. To estimate the response rate to 2 cycles of VTC compared to 2 cycles of VTC/bevacizumab.
II. To evaluate biological markers as related to prognosis and specifically related to
angiogenesis by encouraging concurrent enrollment on the Ewing sarcoma banking studies
(COG-AEWS02B1 and/or COG-AEWS07B1) and ancillary correlative endothelial cell, surrogate
marker, and angiogenic gene studies.
OUTLINE: This is a single therapy feasibility study followed by a randomized controlled
portion. Patients are stratified according to time to disease recurrence (< 2 years vs >= 2
years).
ARM I (Feasibility assessment of VTCB): Patients receive bevacizumab intravenously (IV) over
30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan
hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5.
Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6],
26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12
courses in the absence of disease progression or unacceptable toxicity.
ARM II (VTCB): Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride,
and cyclophosphamide as in Arm I.
ARM III (VTC): Patients receive vincristine sulfate, topotecan hydrochloride, and
cyclophosphamide as in arm I.
After completion of study therapy, patients are followed periodically.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00093821 -
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00030667 -
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
|
Phase 2 | |
Completed |
NCT02116777 -
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT02304458 -
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
|
Phase 1/Phase 2 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Withdrawn |
NCT02011126 -
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00536601 -
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
N/A | |
Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 | |
Completed |
NCT01614795 -
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
|
Phase 2 | |
Withdrawn |
NCT01795430 -
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
|
N/A | |
Completed |
NCT00609141 -
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
|
Phase 1 | |
Active, not recruiting |
NCT00112463 -
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00048984 -
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
|
N/A | |
Completed |
NCT00899990 -
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
|